ICU Medical, Inc. (NASDAQ:ICUI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has received an average recommendation of “Moderate Buy” from the four ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $149.00.

A number of analysts have recently weighed in on ICUI shares. KeyCorp raised their price objective on ICU Medical from $136.00 to $147.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. Raymond James upped their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Finally, Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research note on Thursday, August 8th.

ICU Medical Stock Up 1.3 %

Shares of NASDAQ ICUI opened at $179.20 on Friday. ICU Medical has a 12-month low of $78.28 and a 12-month high of $188.53. The stock’s fifty day simple moving average is $160.16 and its two-hundred day simple moving average is $126.62. The stock has a market capitalization of $4.37 billion, a PE ratio of -73.14 and a beta of 0.66. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The business had revenue of $596.50 million during the quarter, compared to the consensus estimate of $556.64 million. During the same period in the previous year, the company posted $1.58 earnings per share. The firm’s revenue was up 8.6% on a year-over-year basis. As a group, analysts expect that ICU Medical will post 3.76 EPS for the current fiscal year.

Insider Activity

In related news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $156.04, for a total value of $1,872,480.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at $16,320,691.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the transaction, the vice president now owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,552 shares of company stock valued at $6,679,322. Company insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Motco acquired a new stake in shares of ICU Medical during the 1st quarter worth approximately $29,000. Innealta Capital LLC purchased a new stake in ICU Medical during the second quarter worth $32,000. GAMMA Investing LLC boosted its holdings in ICU Medical by 75.1% during the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 133 shares in the last quarter. EntryPoint Capital LLC grew its position in ICU Medical by 731.5% during the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 395 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in ICU Medical by 46.4% in the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 173 shares in the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.